GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (OCSE:NOVO B) » Definitions » Policy Acquisition Expense

Novo Nordisk AS (OCSE:NOVO B) Policy Acquisition Expense


View and export this data going back to 1993. Start your Free Trial

What is Novo Nordisk AS Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.